Biomarkers in GIST: partly ready for prime-time use.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19737947.
- Also identified by DOI 10.1158/1078-0432.CCR-09-1563.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.
Medical subject headings
- Biomarkers, Tumor
- Gastrointestinal Stromal Tumors